Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundación EPIC
About this trial
Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.
Eligibility criteria
Qualifiers
Patients with Signed informed consent and
Patients with >=18 years old and
Patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and
Patients with de novo Coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without ST-segment elevation, and in which an ultrathin strut Sirolimus-eluting stent with bioabsorbable polymer has been used
Disqualifiers
Patients treated percutaneously with any type of stent other than the SupraFlex Cruz® in the 6 months prior to the index procedure in which he or she is included.
Use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s).
Patients treatment for restenosis or stent thrombosis.
Patients presentation in cardiogenic shock or after cardiorespiratory arrest.
Trial design
Treatments tested in this trial
- Supraflex Cruz Sirolimus-eluting Stent
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov